专家表示，随着我国经济社会不断发展，科研体制不断完善，我国癌症防治工作稳步发展。部分瘤种像乳腺癌、前列腺癌的五年生存率已经达到可喜的90% 以上。抗肿瘤创新药物和疗法不断涌现，推动着肿瘤治疗逐步进入慢病管理时代，肿瘤防治正朝着规范化、精准化、创新化方向发展。同时，癌症防治是健 康中国建设的重要课题，通过内科、外科、放疗科等多学科专家联合会诊的多学科协作模式已成为肿瘤治疗的主流趋势，今后，更需锚定群众健康需求，破 解现实挑战，凝聚多方合力，推进防治工作高质量发展。 交流会现场邀请了多位中青年医生入驻"人民好医生・金山茶花计划"临床科研创新中青年专家库。中青年医生代表表示，期盼能有更多投身临床科研与创新 探索的机会，学习借鉴国际前沿的医学技术与理念，共同助力肿瘤防控能力提升。（宋一诺） 在12月21日召开的2025"人民好医生·金山茶花计划"总结交流会上，肺癌、肝胆肿瘤、胃癌、食管癌、乳腺癌、鼻咽癌等领域专家探讨盘点了2025年我国癌 症防控新进展，共同探讨癌症防控新进展，助力推进癌症防控事业高质量发展。 2020年，人民网、人民健康联合肿瘤防控领域权威的专家学者以及战略支持方共同启动了"人民好医生·金山茶花计划 ...

12月21日，2025"人民好医生 金山茶花计划"总结交流在北京举行。现场汇集了肺癌、肝胆肿瘤、胃 癌、食管癌、乳腺癌、妇科肿瘤、泌尿肿瘤、淋巴瘤、鼻咽癌等领域专家，共同探讨癌症防控新进展， 助力推进癌症防控事业高质量发展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉分享了肝胆肿瘤治疗进展。他说，当前肝胆肿瘤 治疗已迈入免疫主导阶段，免疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分 不可切除肿瘤创造根治机会。2025年，国内外权威指南修订、国内多项专家共识出台，进一步推动肝胆 肿瘤诊疗从"经验型"向"循证型"转变。 "得益于精准诊疗的推广、靶向治疗和免疫治疗的应用等，肺癌患者的生存期和生活质量得到了有效延 长和提升。"广东省人民医院首席专家、广东省肺癌研究所名誉所长吴一龙介绍肺癌领域学术科研创新 进展："近年来，SCLC（小细胞肺癌）领域迎来突破性变革，全新的T细胞抗体激活类药物，在SCLC 二线治疗中效果显著，为临床提供了新的治疗范式；在NSCLC（非小细胞肺癌）早中期领域，相关研 究显示纳武利尤单抗联合化疗新辅助治疗能有效提升患者5年生存率，多款创新药物及治疗方案的出 现，推动非小 ...

中国青年报客户端讯（中青报·中青网记者 余冰玥）癌症是危害公众生命健康、制约居民健康水平提升 的重要因素。12月21日，2025"人民好医生·金山茶花计划"总结交流在北京举行。来自肺癌、胃癌、食 管癌、乳腺癌、妇科肿瘤等领域的专家学者共同探讨癌症防控新进展，助力推进癌症防控事业高质量发 展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉介绍，当前，肝胆肿瘤治疗已迈入免疫主导阶 段，免疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分不可切除肿瘤患者创造 了根治机会。2025年，国内外权威指南修订、国内多项专家共识出台，进一步推动肝胆肿瘤诊疗从"经 验型"向"循证型"转变。"未来诊疗需向精准分层、机制协同、全病程管理深化，既要强化高危人群早筛 早诊与科普宣传，优化联合治疗方案，也要鼓励中青年医生投身临床科研创新、紧盯国际前沿。" "得益于精准诊疗的推广、靶向治疗和免疫治疗的应用等，肺癌患者的生存期和生活质量得到了有效延 长和提升。"广东省人民医院首席专家、广东省肺癌研究所名誉所长吴一龙介绍了近年来肺癌领域学术 科研创新进展，在他看来，当前国内研究提供了"中国方案"，"走向全世界还需要迈出更大的 ...

癌症是危害公众生命健康、制约居民健康水平提升的重要因素。12月21日，2025"人民好医生·金山茶花计划"总结交流在北京举行。现场汇集了肺癌、 肝胆肿瘤、胃癌、食管癌、乳腺癌、妇科肿瘤、泌尿肿瘤、淋巴瘤、鼻咽癌等领域专家，共同探讨癌症防控新进展，助力推进癌症防控事业高质量发展。 立足健康需求 共商癌症防治对策 癌症防治是健康中国建设的重要课题，需锚定群众健康需求，破解现实挑战，凝聚多方合力，推进高质量发展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉分享了对于肝胆肿瘤治疗的一些观察与思考。他说，当前肝胆肿瘤治疗已迈入免疫主导阶段，免 疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分不可切除肿瘤创造根治机会。2025年，国内外权威指南修订、国内多项专家共识出 台，进一步推动肝胆肿瘤诊疗从"经验型"向"循证型"转变。樊嘉建议，未来诊疗需向精准分层、机制协同、全病程管理深化，直面百姓健康关切，既要强化 高危人群早筛早诊与科普宣传，优化联合治疗方案，也要鼓励中青年医生投身临床科研创新、紧盯国际前沿。随着人才成长与技术进步，我国肝胆肿瘤防治 事业将实现更高质量发展。 目前，肿瘤治疗已迈入精准化、个 ...

Core Insights - Cancer remains a significant global public health challenge, with the WHO reporting 10 million deaths in 2020, accounting for 1 in 6 deaths globally. Without urgent action, cancer deaths could exceed 18 million by 2050 [1][2] - China has emerged as a key player in cancer research, with a record number of studies presented at major international oncology conferences, indicating its growing influence in the field [1][2] - The introduction of 114 new drugs in the 2025 National Basic Medical Insurance Directory, including 36 cancer drugs, expands treatment options for cancer patients [2] Group 1: Cancer Statistics and Projections - The global burden of cancer is expected to rise, with new cases projected to reach 28.4 million by 2040, a 47% increase from 19.3 million in 2020 [2] - The concept of "5-year survival rate" may evolve to "10-year survival rate," with predictions suggesting a 95% survival rate by 2040 and the potential for cancer to be managed as a chronic disease by 2050 [5] Group 2: Factors Influencing Cancer Development - Five main factors contributing to cancer include external triggers, infection-related factors, hormonal/receptor imbalances, lifestyle-related factors, and psychological/immune-related triggers [3] - The essence of cancer is a disruption in the body's regulatory mechanisms, leading to uncontrolled cell proliferation [3] Group 3: Innovations and Future Directions - Advances in technology, including digital communication, genomics, and artificial intelligence, are expected to enhance cancer survival rates and improve access to quality healthcare [4][7] - The establishment of new cancer classification standards and a focus on integrated treatment approaches are anticipated to transform cancer management and clinical outcomes [4] Group 4: Challenges in Cancer Treatment - The transition from fragmented to integrated treatment poses challenges, including the need for updated knowledge among healthcare professionals and the development of innovative diagnostic and treatment technologies [6][8] - Early diagnosis is critical for improving treatment success rates, with AI playing a role in enhancing the identification of high-risk populations [6] Group 5: Immunotherapy Growth - Immunotherapy has emerged as a significant growth area in cancer treatment, with a projected global market size of $84.9 billion by 2030, driven by advancements in CAR-T, TCR-T, and NK cell therapies [7] - Despite its potential, challenges remain in biomarker selection, toxicity management, and cost control, with breakthroughs expected within the next 25 years [7][8]

证券之星消息，12月9日南向资金增持1.02万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有1天，累计净减持38.28万股。近20个交易日中，获南向资金减持的有10天，累计净减持200.94万 股。截至目前，南向资金持有佰泽医疗（02609.HK）6247.14万股，占公司已发行普通股的4.73%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, positioning itself as a key beneficiary of the policy and providing clear growth opportunities for investors [1][3]. Group 1: Company Developments - The approval allows Guangzhou Taihe Tumor Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1]. - The hospital can now introduce innovative drugs and medical devices in the oncology field, enhancing its competitive advantage and broadening its business scope [1][2]. Group 2: Industry Implications - The "Hong Kong-Macao Drug and Medical Device Access" initiative aims to improve the quality of medical services and align domestic treatments with international standards, particularly in oncology [2][3]. - The initiative is expected to reduce the treatment time gap between mainland China and international markets, particularly for diseases like breast cancer and lung cancer, thereby enhancing patient treatment options [2]. - The increased accessibility of cross-border medical resources will likely attract more patients to hospitals with such capabilities, creating a "regional treatment center" effect and increasing overall service intensity [2][3].

Core Viewpoint - The stock of Meizhong Jiahe (02453) opened over 6% higher following the approval of its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Pass" designated medical institution list [1] Group 1: Company Developments - Meizhong Jiahe's stock rose by 6.12%, reaching HKD 2.08, with a trading volume of HKD 100,700 [1] - The approval allows Guangzhou Taihe Oncology Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, enhancing its competitive advantage in the oncology field [1] Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Pass" is a key initiative under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] - Designated medical institutions in the Greater Bay Area can leverage special pharmaceutical policies, allowing them to access advanced medical solutions [1] - The initiative aims to broaden the business scope of qualified institutions and provide urgently needed medications to more oncology patients, thereby strengthening the overall competitive landscape in the oncology medical sector [1]

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 美中嘉和（02453）早盘高开，截至发稿，股价上涨8.67%，报2.13港元，成交额66.46万港元。 美中嘉和发布公告，公司子公司广州泰和肿瘤医院于2025年12月8日，获广东省卫生健康委员会与广东 省药品监督管理局批准进入粤港澳大湾区"港澳药械通"指定医疗机构名单。 "港澳药械通"是《粤港澳大湾区药品医疗器械监管创新发展工作方案》的核心落地举措，进入名单的粤 港澳大湾区的指定医疗机构，可经审批进口使用粤港澳大湾区专项医药政策，允许指定医疗机构经审批 使用港澳已上市的临床急需药品及具有先进性的医疗器械。 客户端 美中嘉和（02453）早盘高开，截至发稿，股价上涨8.67%，报2.13港元，成交额66.46万港元。 美中嘉和发布公告，公司子公司广州泰和肿瘤医院于2025年12月8日，获广东省卫生健康委员会与广东 省药品监督管理局批准进入粤港澳大湾区"港澳药械通"指定医疗机构名单。 "港澳药械通"是《粤港澳大湾区药品医疗器械监管创新发展工作方案》的核心落地举措，进入名单的粤 港澳大湾区的指定医疗机构，可经审批进口使用粤港澳大湾区专项医药政策，允许指定医疗 ...

美中嘉和(02453)高开逾6%，截至发稿，涨6.12%，报2.08港元，成交额10.07万港元。 本次资格认定使公司成为具备港澳创新药械使用资质的专业肿瘤医疗机构。公司可率先引进与使用已在 中国港澳上市、境内尚未获批的肿瘤领域急需药械，包括新型原研药等，进一步拓宽业务边界，与市场 形成差异化竞争优势，为更多的肿瘤患者提供急需药品，同时强化公司在肿瘤医疗领域的竞争优势。 "港澳药械通"是《粤港澳大湾区药品医疗器械监管创新发展工作方案》的核心落地举措，进入名单的粤 港澳大湾区的指定医疗机构，可经审批进口使用粤港澳大湾区专项医药政策，允许指定医疗机构经审批 使用港澳已上市的临床急需药品及具有先进性的医疗器械。 消息面上，美中嘉和发布公告，公司子公司广州泰和肿瘤医院于2025年12月8日，获广东省卫生健康委 员会与广东省药品监督管理局批准进入粤港澳大湾区"港澳药械通"指定医疗机构名单。 ...